



# Single-Port Robot-Assisted Post-Chemotherapy Unilateral Retroperitoneal Lymph Node Dissection: Feasibility and Surgical Considerations

Sisto Perdonà<sup>1</sup>, Alessandro Izzo<sup>1</sup>, Roberto Contieri<sup>1</sup>, Francesco Passaro<sup>1</sup>, Savio Domenico Pandolfo<sup>2</sup>, Roberto Corrado<sup>3</sup>, Giovanna Canfora<sup>3</sup>, Rocco Damiano<sup>4</sup>, Riccardo Autorino<sup>5</sup>, Gianluca Spena<sup>1</sup>

<sup>1</sup> Department of Urology, Istituto Nazionale Tumori di Napoli, IRCCS, Fondazione "G. Pascale", Napoli, Italy; <sup>2</sup> Department of Neurosciences and Reproductive Sciences and Odontostomatology, Federico II University of Naples, Naples, Italy; <sup>3</sup> Department of Anesthesiology, Istituto Nazionale Tumori di Napoli, IRCCS, Fondazione "G. Pascale", Napoli, Italy; <sup>4</sup> Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy; <sup>5</sup> Department of Urology, Rush University Medical Center, Chicago, IL, USA

## ABSTRACT

**Introduction:** Retroperitoneal lymph node dissection (RPLND) is indicated for testicular cancer patients with residual masses post-chemotherapy or stage I-II non-seminomatous germ cell tumors (NSGCT) (1, 2). Open RPLND remains the standard but carries significant morbidity. The laparoscopic approach, while minimally invasive, presents notable technical challenges (3). Robotic-assisted RPLND (rRPLND) offers a minimally invasive alternative with comparable oncological outcomes (4, 5). The Da Vinci Single Port (SP) system presents new possibilities for reducing surgical morbidity (6, 7).

**Methods:** We report a case of SP-rRPLND using a unilateral modified template and a lower anterior access (LAA) in a 41-year-old man with NSGCT (pT2, UICC Stage IB) who underwent left orchiectomy, followed by adjuvant chemotherapy. A CT scan revealed a 3.5 cm residual retroperitoneal mass in the left hilar region.

The surgical procedure, performed with the Da Vinci SP system, involved a 2.5 cm McBurney incision for retroperitoneal access. Instrument configuration followed a "Camera below" setting. The unilateral left-sided modified template guided dissection from the aortic bifurcation to the renal hilum, preserving vascular structures. A 3,5 cm residual mass and para-aortic nodes were excised with the help of flexible Greena® applicator for clips.

**Results:** Anesthetic management prioritized opioid-sparing techniques to enhance recovery. The patient received regional anesthesia, multimodal analgesia, and had an NRS pain score of 0 at discharge.

The console time was 79 minutes, with minimal blood loss and no complications. The patient resumed oral intake on postoperative day 1 and was discharged on day 2. Postoperative recovery was uneventful, with no complications or need for conversion to open or laparoscopic surgery.

Final histopathological examination revealed a germ cell tumor with features suggestive of immature teratoma, along with over 10 lymph nodes showing sinus histiocytosis. At six months post-RPLND, the patient remains disease-free, with a good general condition and no new symptoms. Tumor markers (AFP, -hCG, LDH) are within normal limits, and CT imaging shows **no evidence** of

recurrence or residual retroperitoneal masses. Renal function and hormonal profile are stable. Given prior chemotherapy exposure, cardiovascular monitoring is advised. Follow-up will continue with clinical exams and tumor markers every 3-4 months, with the next CT scan planned at 12 months, unless symptoms warrant earlier imaging.

**Conclusions:** As far as we know this is the first reported case of SP-rRPLND in Europe. The LAA provides safe access while minimizing morbidity, potentially improving recovery (8). A unilateral approach, avoiding transperitoneal access, may further reduce morbidity (9). Future studies should validate long-term oncological outcomes and compare SP-rRPLND with multiport and open approaches. SP-rRPLND represents a promising advancement in minimally invasive testicular cancer surgery.

## Data Availability

<https://zenodo.org/records/14841220>

## Acknowledgments

We thank Alessandra Trocino, librarian at the Istituto Nazionale Tumori di Napoli, IRCCS "G. Pascale", Italy, for her bibliographic assistance.

## CONFLICT OF INTEREST

None declared.

## REFERENCES

1. Tufano A, Cilio S, Spena G, Izzo A, Castaldo L, Grimaldi G, et al. Unilateral Post-Chemotherapy Robot-Assisted Retroperitoneal Lymph Node Dissection for Stage II Non-Seminomatous Germ Cell Tumors: Sexual and Reproductive Outcomes. *Cancers (Basel)*. 2024;16:2231. doi: 10.3390/cancers16122231.
2. Melão BVLA, de Amorim LGCR, Sanches MR, Gomes GV, Gewehr DM, Moreira LHO, et al. Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II A/B Seminomas: A Systematic Review and Meta-Analysis. *Int Braz J Urol*. 2024;50:415-32. doi: 10.1590/S1677-5538.IBJU.2024.0134.
3. Santos VE, Fornazieri L, Brazão ES Jr, Pinto PR Neto, da Costa WH, Zequi SC. Primary laparoscopic RPLND for pure seminoma metastasis: feasibility of supine and lateral approaches. *Int Braz J Urol*. 2023;49:269-70. doi: 10.1590/S1677-5538.IBJU.2022.0370.
4. Gomes DC, Da Costa WH, Brazão ES Jr, Vergamini LB, Ricci BV, Zequi SC. Robot-assisted retroperitoneal lymphadenectomy (RPLND): video case report. *Int Braz J Urol*. 2021;47:907. doi: 10.1590/S1677-5538.IBJU.2020.0828.
5. Ghoreifi A, Sheybaee Moghaddam F, Mitra AP, Khanna A, Singh A, Chavarriaga J, et al. Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer: A Worldwide Multicenter Study. *Eur Urol Focus*. 2024:S2405-4569(24)00241-4. doi: 10.1016/j.euf.2024.11.001.
6. Ditunno F, Franco A, Licari LC, Bologna E, Manfredi C, Katz DO, et al. Implementation of single-port robotic urologic surgery: experience at a large academic center. *J Robot Surg*. 2024;18:119. doi: 10.1007/s11701-024-01884-z.
7. Perdonà S, Izzo A, Tufano A, Passaro F, Quarto G, Aveta A, et al. Advancing Surgical Management of Penile Cancer: Single Port Bilateral Inguinal Lymph Node Dissection. *Int Braz J Urol*. 2025;51:e20240663. doi: 10.1590/S1677-5538.IBJU.2024.0663.
8. Pellegrino AA, Chen G, Morgantini L, Calvo RS, Crivellaro S. Simplifying Retroperitoneal Robotic Single-port Surgery: Novel Supine Anterior Retroperitoneal Access. *Eur Urol*. 2023;84:223-8. doi: 10.1016/j.eururo.2023.05.006.
9. Masterson TA, Cary C. The Use of Modified Templates in Early and Advanced Stage Nonseminomatous Germ Cell Tumor. *Adv Urol*. 2018;2018:6783147. doi: 10.1155/2018/6783147.

---

**Correspondence address:**

**Gianluca Spena, MD**

Department of Urology, Istituto Nazionale Tumori IRCCS

Fondazione G. Pascale,

Via Mariano Semmola 53.

80131, Naples, Italy

E-mail: spena.dr@gmail.com

---

Submitted for publication:  
February 22, 2025

---

Accepted:  
February 25, 2025

---

Published as Ahead of Print:  
March 20, 2025

---

**ARTICLE INFO**

 **Gianluca Spena**

<https://orcid.org/0000-0002-6714-9315>

Available at: [http://www.intbrazjurol.com.br/video-section/20250091\\_Spena\\_et\\_al](http://www.intbrazjurol.com.br/video-section/20250091_Spena_et_al)